髓系来源的抑制细胞在肝病发病中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2018.05.044

实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (5): 813-816.doi: 10.3969/j.issn.1672-5069.2018.05.044

髓系来源的抑制细胞在肝病发病中的作用研究进展^*

高苗苗, 张纪元综述, 邹正升审校

100039 北京市北京大学解放军第302医院教学医院非感染性肝病诊疗中心（高苗苗,邹正升）; 感染病诊疗与研究中心（张纪元）

收稿日期:2017-02-20 出版日期:2018-09-10 发布日期:2018-09-27
通讯作者: 邹正升,E-mail: zszou302@163.com
作者简介:高苗苗，女，25岁，硕士研究生。主要从事酒精性肝病致病机制与治疗学研究。E-mail: gmm302@163.com
基金资助:
国家自然科学基金面上项目（编号：81670527）

Myeloid-derived suppressor cells in the pathogenesis of liver diseases

Gao Miaomiao, Zhang Jiyuan, Zou Zhengsheng.

Center for Diagnosis and Treatment of Non-Infectious Liver Disease,302nd Hospital,Beijing 100039,China

Received:2017-02-20 Online:2018-09-10 Published:2018-09-27

摘要/Abstract

摘要： 髓系来源的抑制细胞来源于骨髓祖细胞和未成熟的髓系细胞。近年来的研究表明,该细胞参与调节多种肝脏疾病的病理变化。本文系统地归纳了髓系来源的抑制细胞的历史、分群、作用机制和当前该细胞在各种肝病发病中的免疫调控作用及其与疾病进展的关系。

关键词: 肝病, 髓系来源的抑制细胞, 免疫调节

Abstract: Myeloid derived suppressor cells （MDSC） are the kind of immature myeloid cells and progenitor cells from bone marrow. Recent studies found that MDSC were involved in the regulation of pathological changes of various liver diseases. This article systematically summarized the history,clustering and mechanism of MDSC,and the immunoregulatory effects of these cells in the pathogenesis and progression of various liver diseases.

Key words: Liver diseases, Myeloid derived suppressor cells, Immunoregulation

高苗苗, 张纪元综述, 邹正升审校. 髓系来源的抑制细胞在肝病发病中的作用研究进展^*[J]. 实用肝脏病杂志, 2018, 21(5): 813-816.

Gao Miaomiao, Zhang Jiyuan, Zou Zhengsheng.. Myeloid-derived suppressor cells in the pathogenesis of liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 813-816.

参考文献

[1] Kong YY,Fuchsberger M, Xiang SD, et al.Myeloid derived suppressor cells and their role in diseases.Curr Med Chem,2013,20(11):1437-1444.
[2] Boros P,Ochando JC,Chen SH,et al.Myeloid-derived suppressor cells:natural regulators for transplant tolerance. Hum Immunol,2010,71(11):1061-1066.
[3] Talmadge JE,Gabrilovich DI.History of myeloid-derived suppressor cells. Nat Rev Cancer,2013,13(10):739-752.
[4] Laoui D,Van Overmeire E,Movahedi K,et al.Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology,2011,216(11):1192-1202.
[5] Serafini P,Carbley R,Noonan KA,et al.High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res,2004,64(17):6337-6343.
[6] Kowanetz M,Wu X,Lee J,et al.Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.Proc Natl Acad Sci U S A,2010,107(50):21248-21255.
[7] Jin H,Aiyer A,Su J,et al.A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature.J Clin Invest,2006,116(3):652-662.
[8] Delano MJ,Scumpia PO,Weinstein JS,et al.MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med,2007,204(6):1463-1474.
[9] Gabrilovich DI,Nagaraj S.Myeloid-derived suppressor cells as regulators of the immune system.Nat Rev Immunol,2009,9(3):162-174.
[10] Gabrilovich DI,Bronte V,Chen SH,et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res,2007,67(1):425;author reply 426.
[11] Youn JI,Nagaraj S,Collazo M,et al.Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol,2008,181(8):5791-5802.
[12] Dumitru CA,Moses K,Trellakis S,et al.Neutrophils and granulocytic myeloid-derived suppressor cells:immunophenotyping,cell biology and clinical relevance in human oncology. Cancer Immunol Immunother,2012,61(8):1155-1167.
[13] Rodriguez PC,Ernstoff MS,Hernandez C,et al.Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.Cancer Res,2009,69(4):1553-1560.
[14] Zhao F,Hoechst B, Duffy A, et al.S100A9 a new marker for monocytic human myeloid-derived suppressor cells.Immunology,2012,136(2):176-183.
[15] Mirza N, Fishman M, Fricke I, et al.All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res,2006,66(18):9299-9307.
[16] Nagaraj S,Gupta K, Pisarev V, et al.Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med,2007,13(7):828-835.
[17] Ostrand-Rosenberg S,Sinha P.Myeloid-derived suppressor cells:linking inflammation and cancer.J Immunol,2009,182(8):4499-4506.
[18] Srivastava MK,Sinha P,Clements VK,et al.Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.Cancer Res,2010,70(1):68-77.
[19] Serafini P,Mgebroff S,Noonan K,et al.Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.Cancer Res,2008,68(13):5439-5449.
[20] Li H,Han Y,Guo Q,et al.Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.J Immunol,2009,182(1):240-249.
[21] Nausch N,Galani IE,Schlecker E,et al.Mononuclear myeloid derived “suppressor” cells express RAE-1 and activate natural killer cells. Blood,2008,112(10):4080-4089.
[22] Shen P,Wang A,He M,et al.Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res,2014,44(6):639-650.
[23] Xu Y,Zhao W,Xu J,et al.Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2.Oncotarget,2016,7(8):8866-8878.
[24] Kapanadze T,Gamrekelashvili J,Ma C,et al.Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.J Hepatol,2013,59(5):1007-1013.
[25] Ma S,Cheng Q,Cai Y,et al.IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma.Cancer Res,2014,74(7):1969-1982.
[26] Hoechst B,Voigtlaender T,Ormandy L,et al.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology,2009,50(3):799-807.
[27] Hoechst B,Ormandy LA,Ballmaier M,et al.A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+)T cells.Gastroenterology,2008,135(1):234-243.
[28] Arihara F,Mizukoshi E,Kitahara M,et al.Increase in CD14+
HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.Cancer Immunol Immunother,2013,62(8):1421-1430.
[29] Chen S,Akbar S,Abe M,et al.Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol,2011,166(1):134-142.
[30] Kong X,Sun R,Chen Y,et al.Gammadelta T cells drive myeloid-
derived suppressor cell-mediated CD8+T cell exhaustion in hepatitis B virus-induced immunotolerance. J Immunol,2014,193(4):1645-1653.

髓系来源的抑制细胞在肝病发病中的作用研究进展^*

Myeloid-derived suppressor cells in the pathogenesis of liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	丁雯瑾, 范建高. 胆汁淤积性肝病相关并发症的处理^*[J]. 实用肝脏病杂志, 2019, 22(6): 938-940.
[5]	中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 实用肝脏病杂志, 2019, 22(5): 624-635.
[6]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[7]	陆伦根. 胆汁淤积性肝病的正确认识与科学管理[J]. 实用肝脏病杂志, 2019, 22(5): 754-757.
[8]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[9]	唐承薇. 慢性肝病与血小板减少：临床处理观念的转变[J]. 实用肝脏病杂志, 2019, 22(4): 457-458.
[10]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.
[11]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[12]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[13]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[14]	王海舫, 杨大伟, 贾蓓, 张岁, 柳立平, 马文波, 解从君, 刘明书. 营养支持联合美他多辛治疗酒精性肝病患者肝功能和外周血细胞参数的变化[J]. 实用肝脏病杂志, 2019, 22(3): 381-384.
[15]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.